Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 16/20 | 0.58 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.44 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.44 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.44 |
| ▸ | PTGES | O14684 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16655881 | 0.83 | NISCH (0.48) | IDO1CYP3A4ADRA2AADRA2B | |
| SCHEMBL30320872 | 0.75 | IDO1 (0.49) | IDO1CYP3A4ADRA2AADRA2B | |
| SCHEMBL30617847 | 0.75 | PTGES (0.50) | ESR2PTGES | |
| SCHEMBL16655879 | 0.73 | IDO1 (0.48) | IDO1CYP3A4ADRA2AADRA2B | |
| SCHEMBL15124655 | 0.73 | IDO1 (0.48) | IDO1CYP3A4ADRA2A | |
| SCHEMBL13517203 | 0.73 | IDO1 (0.66) | IDO1CYP3A4ADRA2AADRA2B | |
| SCHEMBL1948725 | 0.73 | IDO1 (1.00) | IDO1CYP3A4ADRA2AADRA2B | |
| SCHEMBL26259992 | 0.72 | ADRA2A (0.66) | IDO1CYP3A4ADRA2AADRA2B | |
| SCHEMBL26259980 | 0.72 | IDO1 (0.64) | IDO1CYP3A4ADRA2AADRA2B | |
| SCHEMBL1951228 | 0.72 | IDO1 (1.00) | IDO1CYP3A4ADRA2AADRA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113166114-B | Cyclic tetramer compounds as inhibitors of proprotein convertase subtilisin/KEXIN type 9 (PCSK 9) for the treatment of metabolic disorders | 诺华股份有限公司 | 2025-01-03 | — | — | CN | disclosed |
| EP-2493862-B1 | IMIDAZOLE DERIVATIVES AS IDO INHIBITORS | NEWLINK GENETICS CORP (US) | 2016-10-05 | — | — | EP | disclosed |
| EP-2493862-B1 | IMIDAZOLE DERIVATIVES AS IDO INHIBITORS | NEWLINK GENETICS CORP (US) | 2016-10-05 | — | — | EP | disclosed |
| US-8722720-B2 | Imidazole derivatives as IDO inhibitors | NEWLINK GENETICS CORPORATION (US) | 2014-05-13 | — | — | US | disclosed |
| US-8722720-B2 | Imidazole derivatives as IDO inhibitors | NEWLINK GENETICS CORPORATION (US) | 2014-05-13 | — | — | US | disclosed |
| US-8722720-B2 | Imidazole derivatives as IDO inhibitors | NEWLINK GENETICS CORPORATION (US) | 2014-05-13 | — | — | US | disclosed |
| US-20120277217-A1 | Imidazole Derivatives as IDO Inhibitors | NEWLINK GENETICS CORPORATION (US) | 2012-11-01 | — | — | US | disclosed |
| US-20120277217-A1 | Imidazole Derivatives as IDO Inhibitors | NEWLINK GENETICS CORPORATION (US) | 2012-11-01 | — | — | US | disclosed |
| US-20120277217-A1 | Imidazole Derivatives as IDO Inhibitors | NEWLINK GENETICS CORPORATION (US) | 2012-11-01 | — | — | US | disclosed |
| EP-2493862-A1 | IMIDAZOLE DERIVATIVES AS IDO INHIBITORS | Newlink Genetics Corporation (US) | 2012-09-05 | — | — | EP | disclosed |
| WO-2011056652-A1 | IMIDAZOLE DERIVATIVES AS IDO INHIBITORS | NEWLINK GENETICS (US) | 2011-05-12 | — | — | WO | disclosed |
| WO-2011056652-A1 | IMIDAZOLE DERIVATIVES AS IDO INHIBITORS | NEWLINK GENETICS (US) | 2011-05-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120277217-A1 | Imidazole Derivatives as IDO Inhibitors | IDO1, IDO2, INMT | IDO1 1/4885CYP3A4 229/4885ESR2 4103/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.